drugset

drugset / Trial / NCT00935506

Ex Vivo Human Thrombosis Chamber Study

NCT00935506 ↗

Phase 1 Completed 15 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelBasic science

Summary

Purpose of study is to evaluate a thrombosis chamber model

Timeline

Start: 2009-07
Primary completion: 2009-10
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Aspirin	Small molecule	325 mg	Oral
Background	Clopidogrel	Small molecule	75 mg	Oral

Indications